Metabolic / Obesity Programs
Undisclosed Metabolic Disease / Obesity
Preclinical / Early ClinicalResearch ongoing
Key Facts
Indication
Undisclosed Metabolic Disease / Obesity
Phase
Preclinical / Early Clinical
Status
Research ongoing
Company
About Terns Pharmaceuticals
Terns Pharmaceuticals is a publicly traded, clinical-stage biotech company with a mission to advance transformative medicines by reimagining known biology. Its core strategy involves selecting de-risked, clinically validated targets and applying innovative medicinal chemistry to develop potentially best-in-class small-molecule drugs. The company's most significant achievement is the advancement of TERN-701 for CML, which has culminated in a definitive acquisition agreement with Merck, validating its platform and pipeline. Terns operates with a focused, agile team and a culture designed to accelerate development timelines in high-need therapeutic areas.
View full company profile